Literature DB >> 20833502

Synchronous resection for colorectal liver metastases: the future.

S Pathak1, G Sarno, Q M Nunes, G J Poston.   

Abstract

Colorectal Cancer is a common malignancy. Many patients have metastatic disease at presentation and a significant proportion subsequently go onto develop metastatic disease, following surgery for the primary disease. Some groups advocate that synchronous metastatic disease should be resected at the same time as the primary, whereas others believe that outcomes are better following delayed resection for metastatic disease. The following review aims to outline the arguments in favour of both and to suggest some broad guidelines.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20833502     DOI: 10.1016/j.ejso.2010.08.137

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

Review 1.  Simultaneous laparoscopic resection of primary colorectal cancer and associated liver metastases: a systematic review.

Authors:  R M Lupinacci; W Andraus; L B De Paiva Haddad; L A Carneiro D' Albuquerque; P Herman
Journal:  Tech Coloproctol       Date:  2013-09-21       Impact factor: 3.781

Review 2.  Management of colorectal cancer presenting with synchronous liver metastases.

Authors:  Ajith K Siriwardena; James M Mason; Saifee Mullamitha; Helen C Hancock; Santhalingam Jegatheeswaran
Journal:  Nat Rev Clin Oncol       Date:  2014-06-03       Impact factor: 66.675

3.  Laparoscopic versus open hepatectomy with or without synchronous colectomy for colorectal liver metastasis: a meta-analysis.

Authors:  MingTian Wei; YaZhou He; JiaRong Wang; Nan Chen; ZongGuang Zhou; ZiQiang Wang
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

4.  The interval approach: an adaptation of the liver-first approach to treat synchronous liver metastases from rectal cancer.

Authors:  Mathieu D'Hondt; Valerio Lucidi; Koen Vermeiren; Bert Van Den Bossche; Vincent Donckier; Gregory Sergeant
Journal:  World J Surg Oncol       Date:  2017-03-02       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.